Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.

Q2 Medicine
Cancer Microenvironment Pub Date : 2014-08-01 Epub Date: 2013-11-10 DOI:10.1007/s12307-013-0140-4
Paulette Mhawech-Fauceglia, Dan Wang, Damanzoopinder Samrao, Grace Kim, Kate Lawrenson, Teodulo Meneses, Song Liu, Annie Yessaian, Tanja Pejovic
{"title":"Clinical Implications of Marker Expression of Carcinoma-Associated Fibroblasts (CAFs) in Patients with Epithelial Ovarian Carcinoma After Treatment with Neoadjuvant Chemotherapy.","authors":"Paulette Mhawech-Fauceglia,&nbsp;Dan Wang,&nbsp;Damanzoopinder Samrao,&nbsp;Grace Kim,&nbsp;Kate Lawrenson,&nbsp;Teodulo Meneses,&nbsp;Song Liu,&nbsp;Annie Yessaian,&nbsp;Tanja Pejovic","doi":"10.1007/s12307-013-0140-4","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma (pos) . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p = 0.0072]. Cases with combined FAP stroma (pos) and FAP tumor (neg) had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p = 0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p = 0.0487] compared to all the others. Cases with combined FAP stroma (neg) and FAP tumor (neg) were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p = 0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy. </p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"7 1-2","pages":"33-9"},"PeriodicalIF":0.0000,"publicationDate":"2014-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-013-0140-4","citationCount":"24","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12307-013-0140-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/11/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 24

Abstract

Cancer-associated fibroblasts (CAFs) play an important role in tumor initiation and progression. The aim of this study is to explore the role of 2 CAF markers, fibroblast activated protein (FAP) and α-smooth muscle actin (αSMA), in patients with epithelial ovarian cancer (EOC) post-neoadjuvant chemotherapy. Sixty-six patients with the diagnosis of EOC treated with debulking surgery after neoadjuvant therapy were retrieved from the archives. Immunohistochemistry for FAP and αSMA antibodies were performed on paraffin-embedded tissue. Fisher's exact test was performed to test the association between FAP and αSMA expression and disease status. Kaplan-Meier method with log-rank test was used to check the survival difference between different FAP tumor/stroma expressions. FAP stroma (pos) . expression was strongly associated with higher recurrences rate [OR: 15.95; 95 % CI: 1.521-835.206; p = 0.0072]. Cases with combined FAP stroma (pos) and FAP tumor (neg) had higher death rate [OR: 4.845; 95 % CI: 1.53-16.61; p = 0.0046] and higher recurrence rate [OR: 5.12; 95 % CI: 0.91-54.42; p = 0.0487] compared to all the others. Cases with combined FAP stroma (neg) and FAP tumor (neg) were more likely to have lower recurrence rates [OR: 0.086; 95 % CI: 0.001-0.997; p = 0.0248]. αSMA was expressed by tumor-associated stroma in 95 % of cases and by tumor cells in 9 % of cases. No statistical power was found for αSMA and disease status. Our data indicate that FAP plays an important role in predicting tumor aggressiveness in patients with EOC post-neoadjuvant therapy, and its frequent expression in this malignancy implicates that FAP targeted therapy could be a very attractive strategy.

Abstract Image

Abstract Image

Abstract Image

新辅助化疗后上皮性卵巢癌患者癌相关成纤维细胞(CAFs)标志物表达的临床意义
癌症相关成纤维细胞(CAFs)在肿瘤的发生和发展中起着重要作用。本研究旨在探讨2种CAF标志物成纤维细胞活化蛋白(FAP)和α-平滑肌肌动蛋白(αSMA)在上皮性卵巢癌(EOC)新辅助化疗后的作用。我们从档案中检索了66例诊断为EOC的患者,在新辅助治疗后进行了减体积手术。石蜡包埋组织进行FAP和α - sma抗体免疫组化。采用Fisher精确检验检验FAP和αSMA表达与疾病状态的关系。采用Kaplan-Meier法和log-rank检验检验不同FAP肿瘤/基质表达间的生存差异。FAP基质(pos)。表达与高复发率密切相关[OR: 15.95;95% ci: 1.521-835.206;p = 0.0072]。合并FAP间质(pos)和FAP肿瘤(阴性)的患者死亡率更高[OR: 4.845;95% ci: 1.53-16.61;p = 0.0046]和较高的复发率[OR: 5.12;95% ci: 0.91-54.42;P = 0.0487]。合并FAP间质(阴性)和FAP肿瘤(阴性)的患者复发率更低[OR: 0.086;95% ci: 0.001-0.997;p = 0.0248]。95%的肿瘤相关基质表达α - sma, 9%的肿瘤细胞表达α - sma。α - sma与疾病状态无统计学意义。我们的数据表明,FAP在预测新辅助治疗后EOC患者的肿瘤侵袭性方面起着重要作用,它在这种恶性肿瘤中的频繁表达表明FAP靶向治疗可能是一种非常有吸引力的策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Microenvironment
Cancer Microenvironment Medicine-Oncology
CiteScore
4.90
自引率
0.00%
发文量
0
期刊介绍: Cancer Microenvironment is the official journal of the International Cancer Microenvironment Society (ICMS). It publishes original studies in all aspects of basic, clinical and translational research devoted to the study of cancer microenvironment. It also features reports on clinical trials. Coverage in Cancer Microenvironment includes: regulation of gene expression in the cancer microenvironment; innate and adaptive immunity in the cancer microenvironment, inflammation and cancer; tumor-associated stroma and extracellular matrix, tumor-endothelium interactions (angiogenesis, extravasation), cancer stem cells, the metastatic niche, targeting the tumor microenvironment: preclinical and clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信